HIMS
The FDA just opened the door a crack
The Food and Drug Administration says it’ll hold a July meeting to review whether several peptide injections should be easier for compounding pharmacies to make. Translation: the agency is at least entertaining the idea that some of these buzzy wellness treatments could get a lighter regulatory touch.
Why Hims is suddenly in the group chat
Hims & Hers jumped in premarket after saying it supports the FDA’s plan to clarify the rules around peptide therapies. That makes sense: if the regulatory fog clears, companies selling telehealth-adjacent wellness offerings may have a much cleaner path to market. Investors tend to love anything that turns “maybe someday” into “okay, we can actually do this.”
But this isn’t a free-for-all
The catch? Most of the peptides under review still don’t have the kind of large human clinical trial data that usually makes regulators sleep better at night. The FDA already tightened the screws in 2023 after safety concerns, so this is less a victory lap and more a careful re-check of the rulebook.
Big picture
For Hims, the headline is less “all-clear” and more “the FDA is at least willing to talk.” And in markets, even a hint of a policy tailwind can be worth a little extra oxygen — especially when the stock is already tied to the next shiny health trend.